Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
RemeGen Co Ltd (688331)
Track today's live RemeGen (688331) share price, performance and key data on this page with our current Shanghai:688331 stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the RemeGen share price on the Shanghai exchange. Use the dropdown to switch exchange for the 688331 share price, head to our technical summary section, which provides analysis on RemeGen share price buy/sell indicators using real-time data (or discuss the RemeGen (688331) stock price today with other investors in the RemeGen SS share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current SS:688331 share price (ISIN: CNE100005B03) to enhance your trading decisions with our free investment tools and resources.
What Is the RemeGen Co Ltd Share Price Today?
The RemeGen share price today is 119.73.
What Is the Stock Symbol for RemeGen Co Ltd
The stock symbol (or 'ticker') for RemeGen Co Ltd is "688331."
What Stock Exchange Does RemeGen Co Ltd Trade On?
RemeGen Co Ltd is listed and trades on the Shanghai stock exchange.
Is RemeGen Co Ltd a Good Stock to Buy?
Determining whether RemeGen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current SS:688331 share price (ISIN: CNE100005B03) to enhance your trading decisions with our free investment tools and resources.
What Is the RemeGen Co Ltd Share Price Today?
The RemeGen share price today is 119.73.
What Is the Stock Symbol for RemeGen Co Ltd
The stock symbol (or 'ticker') for RemeGen Co Ltd is "688331."
What Stock Exchange Does RemeGen Co Ltd Trade On?
RemeGen Co Ltd is listed and trades on the Shanghai stock exchange.
Is RemeGen Co Ltd a Good Stock to Buy?
Determining whether RemeGen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
119.73
-2.02(-1.66%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118.91
122.80
52 wk Range
75.03
157.80
688331 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118.91122.80
52 wk Range
75.03157.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
688331 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
138.72
Upside
+15.86%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Remegen Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Remegen Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Remegen Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Remegen Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Remegen Co Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 138.72
(+15.86% Upside)
Earnings
Latest Release
24/08/2026
EPS / Forecast
7.75 / --
Revenue / Forecast
5.2B / --
Compare 688331 to Peers and Sector
Metrics to compare | 688331 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688331PeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.0x | −12.0x | −0.4x | |
PEG Ratio | 0.02 | 0.06 | 0.00 | |
Price/Book | 7.0x | 5.1x | 2.6x | |
Price / LTM Sales | 7.3x | 17.2x | 3.1x | |
Upside (Analyst Target) | 26.2% | 37.7% | 47.0% | |
Fair Value Upside | Unlock | 2.0% | 5.6% | Unlock |
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the RemeGen (Shanghai: 688331) Share Price Today?
The RemeGen stock price today is 119.73 CNY.
What Stock Exchange Does RemeGen (688331) Trade On?
RemeGen is listed and trades on the Shanghai Stock Exchange.
What Is the Ticker (Stock Symbol) for RemeGen?
The stock symbol (also called a 'ticker') for RemeGen is "688331."
What Is the Current RemeGen Market Capitalisation?
As of today, RemeGen (Shanghai: 688331) market cap is 57.30B CNY.
What Is RemeGen's (688331) Earnings Per Share (TTM)?
The RemeGen EPS is currently 10.39 (Trailing Twelve Months).
When Is the Next RemeGen Earnings Date?
RemeGen's next earnings report will be released on 04/11/2026.
Is 688331 a Buy or Sell From a Technical Analyst Perspective?
Based on today's RemeGen moving averages and other technical indicators, the daily buy/sell signal for 688331 stock is Strong Sell.
How Many Times Has RemeGen Stock Split?
RemeGen has split 0 times. (See the 688331 stock split history page for full effective split date and price information.)
How Many Employees Does RemeGen Have?
RemeGen has 3145 employees, based on their latest Companies House report.
What is the current trading status of RemeGen (Shanghai: 688331)?
As of 28/08/2026, RemeGen (688331) is trading at a share price of 119.73 CNY, with a previous close of 121.75 CNY. The stock has fluctuated within a day range of 118.91 CNY to 122.80 CNY, while its 52-week range spans from 75.03 CNY to 157.80 CNY.
What Is RemeGen (688331) Price Target According to Analysts?
The average 12-month price target for RemeGen is 138.72 CNY, with a high estimate of 161.61 CNY and a low estimate of 96.7 CNY. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +15.86% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.